Eyenovia Begin Period Cash Flow vs Net Income Analysis
EYEN Stock | USD 0.11 0.02 19.05% |
Eyenovia financial indicator trend analysis is much more than just examining Eyenovia latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Eyenovia is a good investment. Please check the relationship between Eyenovia Begin Period Cash Flow and its Net Income accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eyenovia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Eyenovia Stock, please use our How to Invest in Eyenovia guide.
Begin Period Cash Flow vs Net Income
Begin Period Cash Flow vs Net Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Eyenovia Begin Period Cash Flow account and Net Income. At this time, the significance of the direction appears to have pay attention.
The correlation between Eyenovia's Begin Period Cash Flow and Net Income is -0.83. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Net Income in the same time period over historical financial statements of Eyenovia, assuming nothing else is changed. The correlation between historical values of Eyenovia's Begin Period Cash Flow and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Eyenovia are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Begin Period Cash Flow i.e., Eyenovia's Begin Period Cash Flow and Net Income go up and down completely randomly.
Correlation Coefficient | -0.83 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Eyenovia financial statement analysis. It represents the amount of money remaining after all of Eyenovia operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most indicators from Eyenovia's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Eyenovia current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eyenovia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Eyenovia Stock, please use our How to Invest in Eyenovia guide.As of the 25th of November 2024, Sales General And Administrative To Revenue is likely to grow to 2,828, while Selling General Administrative is likely to drop about 7.3 M.
2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 221.6K | 307.4K | 783.2K | 822.4K | Interest Income | 2.5K | 83.3K | 547.6K | 574.9K |
Eyenovia fundamental ratios Correlations
Click cells to compare fundamentals
Eyenovia Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Eyenovia fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 14.7M | 33.9M | 31.7M | 31.0M | 28.8M | 21.0M | |
Other Current Liab | 1.3M | 16.6M | 2.4M | 2.3M | 1.9M | 3.3M | |
Total Current Liabilities | 2.9M | 18.2M | 11.2M | 4.5M | 9.5M | 6.2M | |
Total Stockholder Equity | 11.7M | 15.3M | 20.5M | 17.2M | 9.0M | 12.4M | |
Net Tangible Assets | 16.9M | 11.7M | 15.3M | 20.5M | 23.5M | 24.7M | |
Property Plant And Equipment Net | 230.5K | 396.4K | 1.3M | 3.3M | 5.0M | 5.3M | |
Net Debt | (14.1M) | (27.9M) | (12.3M) | (12.7M) | 1.2M | 1.3M | |
Retained Earnings | (57.7M) | (77.4M) | (90.2M) | (118.2M) | (145.5M) | (138.2M) | |
Accounts Payable | 1.5M | 1.5M | 1.6M | 1.4M | 1.8M | 1.2M | |
Cash | 14.2M | 28.4M | 19.5M | 22.9M | 14.8M | 16.0M | |
Non Current Assets Total | 348.3K | 515.4K | 9.7M | 3.4M | 8.1M | 8.5M | |
Cash And Short Term Investments | 14.2M | 28.4M | 19.5M | 22.9M | 14.8M | 16.0M | |
Common Stock Total Equity | 257.0 | 1.1K | 1.7K | 2.5K | 2.9K | 3.0K | |
Common Stock Shares Outstanding | 14.3M | 21.1M | 26.3M | 33.6M | 41.0M | 21.5M | |
Liabilities And Stockholders Equity | 14.7M | 33.9M | 31.7M | 31.0M | 28.8M | 21.0M | |
Capital Surpluse | 24.4M | 53.4M | 69.4M | 92.7M | 106.7M | 112.0M | |
Other Current Assets | 196.7K | 2.1M | 734.9K | 3.6M | 5.1M | 5.4M | |
Other Stockholder Equity | 69.4M | 92.7M | 110.7M | 135.5M | 154.5M | 82.0M | |
Total Liab | 3.0M | 18.6M | 11.2M | 13.8M | 19.8M | 20.8M | |
Property Plant And Equipment Gross | 230.5K | 396.4K | 1.6M | 3.3M | 7.2M | 7.5M | |
Total Current Assets | 14.3M | 33.4M | 22.0M | 27.6M | 20.7M | 18.3M | |
Common Stock | 1.7K | 2.5K | 2.8K | 3.7K | 4.6K | 4.8K | |
Property Plant Equipment | 36.7K | 230.5K | 396.4K | 1.3M | 1.5M | 1.5M | |
Non Current Liabilities Total | 45.4K | 404.5K | 19.9K | 9.3M | 10.2M | 10.8M | |
Net Invested Capital | 11.7M | 15.8M | 27.6M | 26.0M | 23.3M | 19.9M | |
Net Working Capital | 11.4M | 15.2M | 10.8M | 23.1M | 11.2M | 14.7M | |
Capital Stock | 1.7K | 2.5K | 2.8K | 3.7K | 4.6K | 3.0K |
Pair Trading with Eyenovia
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eyenovia position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eyenovia will appreciate offsetting losses from the drop in the long position's value.Moving together with Eyenovia Stock
Moving against Eyenovia Stock
0.62 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
0.48 | FBRX | Forte Biosciences Trending | PairCorr |
0.34 | GILD | Gilead Sciences | PairCorr |
The ability to find closely correlated positions to Eyenovia could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eyenovia when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eyenovia - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eyenovia to buy it.
The correlation of Eyenovia is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eyenovia moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eyenovia moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eyenovia can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eyenovia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Eyenovia Stock, please use our How to Invest in Eyenovia guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eyenovia. If investors know Eyenovia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eyenovia listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.69) | Revenue Per Share 0.001 | Quarterly Revenue Growth 4 | Return On Assets (0.93) | Return On Equity (9.15) |
The market value of Eyenovia is measured differently than its book value, which is the value of Eyenovia that is recorded on the company's balance sheet. Investors also form their own opinion of Eyenovia's value that differs from its market value or its book value, called intrinsic value, which is Eyenovia's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eyenovia's market value can be influenced by many factors that don't directly affect Eyenovia's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eyenovia's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eyenovia is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eyenovia's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.